Upstate has promoted Ian Ratcliffe to president and chief operating officer, making him responsible for all business operations worldwide, the company said. Most recently, Ratcliffe was Upstate’s executive vice president of sales and innovation, and he served as chief financial officer from 1997 to 2001.
Ratcliffe was the first employee of Argonex, and was instrumental in that company’s eventual merger with Upstate Biotechnology, the company said. Ratcliffe holds an MBA from the University of Virginia.
Genomatica, a computational systems biology company, has named George Church, Leroy Hood, Eugene Myers, and Bernhard Palsson to its scientific advisory board.
Palsson, who will serve as chairman of the board, is a professor of bioengineering and adjunct professor of medicine at the University of California, San Diego, and the co-founder of Genomatica. Palsson holds a PhD in chemical engineering from the University of Wisconsin.
Church is a professor of genetics at Harvard Medical School and director of the Lipper Center for Computational Genetics. Church helped initiate the Human Genome Project in 1984, and helped found the Stanford, MIT, and Waltham Genome Centers, Genomatica said. Church earned his PhD in biochemistry and molecular biology from Harvard.
Hood is co-founder and president of the Institute for Systems Biology. He holds an MD from Johns Hopkins University and a PhD in biochemistry from the California Institute of Technology.
Myers is currently a professor of computer science at the University of California, Berkeley, and former vice president of informatics research at Celera Genomics. He received his PhD in computer science from the University of Colorado.
Beyond Genomics recently announced the formation of a research and development advisory board. Arnold Levine and Jeffrey Friedman will serve as co-chairs of the board, which also includes David Jackson, Jan van der Greef, Victor Dzau, Marc Kirschner, Douglas Lauffenburger, and Christopher Sander.
Beyond Genomics expects the advisory board to make active recommendations for the use of the company’s proprietary Molecular Systems Biology platforms both for internal drug development programs and in research alliances with pharmaceutical companies, the company said in a statement.